1![Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le](https://www.pdfsearch.io/img/e1a580a36e6d3acef9aed84b7e91d3e3.jpg) | Add to Reading ListSource URL: www.anrs.frLanguage: French - Date: 2015-08-31 09:43:58
|
---|
2![Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le](https://www.pdfsearch.io/img/4ca0be19f7777c4423ea07f8d8cb2546.jpg) | Add to Reading ListSource URL: www.anrs.frLanguage: French - Date: 2015-08-31 09:43:58
|
---|
3![Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav](https://www.pdfsearch.io/img/5fe1e2e872e34bc8689936802b0cca4f.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
4![Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1 Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1 ](https://www.pdfsearch.io/img/e68e47ccac33fb828cf030b79caf1753.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:21
|
---|
5![Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I](https://www.pdfsearch.io/img/f2edba1b703eb36b34072d7f4ded7f54.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:11
|
---|
6![Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside](https://www.pdfsearch.io/img/ea7e0a57ead0c5e1fe795ddfcd1c9524.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
7![ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P](https://www.pdfsearch.io/img/c5e756c483bd9b39f54c6028d7480e61.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2015-01-27 14:49:56
|
---|
8![Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C](https://www.pdfsearch.io/img/97d3adc47fc6c54010acb9a2355d8fcc.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:18
|
---|
9![](https://www.pdfsearch.io/img/7a2751a7ab1da7af42c9eba8ba4c6bdd.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:18
|
---|
10![Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia](https://www.pdfsearch.io/img/d89c92398af08a8b010529fbde42b9cf.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:18
|
---|